Evidence map›Paper›PMID 42017265›Full record

ArticleAlimentary pharmacology & therapeutics2026

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes.

Suzanne Sharpton, Luis Antonio Díaz, Kay Pepin, Maral Amangurbanova, Egbert Madamba, Ricki Bettencourt, Seema Singh, Mark Valasek, Mary Dalupang, Kaleb Tesfai and 32 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Total Flavonoids ofNutrients · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Suzanne SharptonDivision of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0001-7722-5716
Luis Antonio DíazMASLD Research Center, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-8540-4930
Kay PepinDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Maral AmangurbanovaIcahn School of Medicine at Mount Sinai, NYC Health+Hospitals Queens, New York, New York, USA.
Egbert MadambaMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Ricki BettencourtMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Seema SinghMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Mark ValasekMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Mary DalupangMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Kaleb TesfaiMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Michael S MiddletonDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Cynthia BehlingDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Winston DunnDivision of Gastroenterology, University of Kansas Health System, Kansas City, Kansas, USA.
Atsushi NakajimaDepartment of Gastroenterology, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0009-0006-6795-8581
Kento ImajoDepartment of Gastroenterology, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0002-1931-6326
Yuji OgawaDepartment of Gastroenterology, Yokohama City University, Yokohama, Japan.
Cyrielle CaussyHospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite, France.
Dina Halegoua-DeMarzioDivision of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Arpan MohantyDivision of Gastroenterology, Boston University, Boston, Massachusetts, USA.
Daniel Q HuangDivision of Gastroenterology and Hepatology, National University of Singapore, Singapore, Singapore.ORCID https://orcid.org/0000-0002-5165-5061
Michael FuchsCentral Virginia Veterans Affairs Healthcare System and Virginia Commonwealth University, Richmond, Virginia, USA.
Bilal HameedDivision of Gastroenterology, University of California San Francisco, San Francisco, California, USA.
Jonathan G StineLate-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Maya BalakrishnanDivision of Gastroenterology, Baylor College of Medicine, Houston, Texas, USA.
Meagan GrayDivision of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Manuel RodriguezFlorida Research Institute, Lakewood Ranch, Florida, USA.
Andre DeLeonPinnacle Clinical Research, San Antonio, Texas, USA.
Rohit PuskoorPinnacle Clinical Research, Austin, Texas, USA.
Raj VuppalanchiDivision of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-0637-1577
Jaideep BehariDepartment of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Lars HansenLate-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Cynthia MillerClinical Trials Manager, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Valentina MediciDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.ORCID https://orcid.org/0000-0001-5438-284X
Souvik SarkarDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA.
Jerome BoursierCentre Hospitalier Universitaire D'angers, HIFIH Laboratory, SFR ICAT 4208, Angers University France, Angers, France.
Monica TincopaMASLD Research Center, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-9954-8548
Veeral AjmeraMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Lisa RichardsMASLD Research Center, University of California San Diego, La Jolla, California, USA.
Claude B SirlinDepartment of Radiology, University of California San Diego, La Jolla, California, USA.
Richard L EhmanDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-7041-5074
Rohit LoombaMASLD Research Center, University of California San Diego, La Jolla, California, USA.
GOLDMINE consortium

Funding

AstraZeneca
6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes.

aimsTo describe the design and rationale of the GOLDMINE study, established to determine whether non-invasive imaging biomarkers predict MASLD progression and liver-related clinical outcomes.

methodsGOLDMINE is an investigator-initiated, multi-centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy-proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration-controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton-density-fat-fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2-year intervals (years 2 and 4), with annual follow-up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted.

resultsThe prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver-related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, with independent central adjudication of all events.

conclusionsGOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI-based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood-based prognostic biomarkers in MASLD.

Indexed as

Elasticity Imaging TechniquesMagnetic Resonance ImagingNon-alcoholic Fatty Liver DiseaseAdultBiomarkersDisease ProgressionFemaleHumansLiver CirrhosisLongitudinal StudiesMaleMiddle AgedProspective StudiesBiomarkersfatty livermetabolic dysfunction‐associated steatotic liver diseaseNAFLDnon‐alcoholic fatty liver diseasenon‐alcoholic steatohepatitis

Identifiers

PMID42017265
PMCPMC13356296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.